Methyl 2-cyano-3,11-dioxo-18-olean-1,12-dien-30-oate (CDODA-Me), a derivative of glycyrrhetinic acid, functions as a potent angiogenesis inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 1, 2010, Pages 172-179

  Pang, Xiufeng ^a   Zhang, Li ^a   Wu, Yougen ^a   Lin, Lei ^a   Li, Jingjie ^a   Qu, Weijing ^a   Safe, Stephen ^b   Liu, Mingyao ^a,b  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; GLYCYRRHETINIC ACID DERIVATIVE; HEPARIN; MAMMALIAN TARGET OF RAPAMYCIN; METHYL 2 CYANO 3,11 DIOXO 18 OLEAN 1,12 DIEN 30 OATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR; ANGIOGENESIS INHIBITOR; GLYCYRRHETINIC ACID; METHYL 2-CYANO-3,11-DIOXO-18BETA-OLEAN-1,12-DIEN-30-OATE; MITOGEN ACTIVATED PROTEIN KINASE; MTOR PROTEIN, HUMAN; MTOR PROTEIN, RAT; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY PROLIFERATION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LAMELLIPODIUM; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CAPILLARY; CELL CYCLE; CELL MOTION; CELL SURVIVAL; CHEMOTAXIS; CYTOSKELETON; DRUG EFFECTS; GENETICS; IN VITRO STUDY; MALE; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; RAT; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CAPILLARIES; CASPASES; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CYTOSKELETON; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLYCYRRHETINIC ACID; IMMUNOHISTOCHEMISTRY; IN VITRO TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 77957242580     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.171066     Document Type: Article

References (34)

1. Albini A, Dell'Eva R, Vené R, Ferrari N, Buhler DR, Noonan DM, and Fassina G (2006) Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-κB and Akt as targets. Faseb J 20:527-529.
2. Aljada A, O'Connor L, Fu YY, and Mousa SA (2008) PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF- and VEGF-mediated angiogenesis. Angiogenesis 11:361-367.
3. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, et al. (2008) Selective activation of peroxisome proliferator-activated receptor (PPAR)α and PPARγ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57:1394-1404.
4. Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438:932-936.
5. Casanovas O, Hicklin DJ, Bergers G, and Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299-309.
6. Chintalgattu V, Harris GS, Akula SM, and Katwa LC (2007) PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc Res 74:140-150.
7. Chintharlapalli S, Papineni S, Abdelrahim M, Abudayyeh A, Jutooru I, Chadalapaka G, Wu F, Mertens-Talcott S, Vanderlaag K, Cho SD, et al. (2009) Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer 125:1965-1974.
8. Chintharlapalli S, Papineni S, Jutooru I, McAlees A, and Safe S (2007a) Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor γ agonists in colon cancer cells. Mol Cancer Ther 6:1588-1598.
9. Chintharlapalli S, Papineni S, Liu S, Jutooru I, Chadalapaka G, Cho SD, Murthy RS, You Y, and Safe S (2007b) 2-Cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor γ in colon and pancreatic cancer cells. Carcinogenesis 28:2337-2346. (Pubitemid 350111592)
10. Christodoulides C and Vidal-Puig A (2010) PPARs and adipocyte function. Mol Cell Endocrinol 318:61-68.
11. Dancey JE, Curiel R, and Purvis J (2009) Evaluating temsirolimus activity in multiple tumors: a review of clinical trials. Semin Oncol 36:S46-S58.
12. Ferrara N and Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974.
13. Giaginis C, Tsantili-Kakoulidou A, and Theocharis S (2008) Peroxisome proliferator-activated receptor-γ ligands: potential pharmacological agents for targeting the angiogenesis signaling cascade in cancer. PPAR Res 2008:431763.
14. Hafner C, Reichle A, and Vogt T (2005) New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARγ agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy. Curr Cancer Drug Targets 5:393-419.
15. Hanahan D and Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70.
16. Helmlinger G, Endo M, Ferrara N, Hlatky L, and Jain RK (2000) Formation of endothelial cell networks. Nature 405:139-141.
17. Huang PH, Sata M, Nishimatsu H, Sumi M, Hirata Y, and Nagai R (2008) Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed Pharmacother 62:46-52.
18. Laquente B, Viñals F, and Germà JR (2007) Metronomic chemotherapy: an antiangiogenic scheduling. Clin Transl Oncol 9:93-98.
19. Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, Fujise K, and Liu M (2009a) Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 69:518-525.
20. Pang X, Yi Z, Zhang J, Lu B, Sung B, Qu W, Aggarwal BB, and Liu M (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res 70:1951-1959.
21. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, and Liu M (2009b) Acetyl-11-keto-β-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69:5893-5900.
22. Papineni S, Chintharlapalli S, and Safe S (2008) Methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate is a peroxisome proliferator-activated receptor-gamma agonist that induces receptor-independent apoptosis in LNCaP prostate cancer cells. Mol Pharmacol 73:553-565.
23. Patan S (2004) Vasculogenesis and angiogenesis. Cancer Treat Res 117:3-32.
24. Pinkaew D, Cho SG, Hui DY, Wiktorowicz JE, Hutadilok-Towatana N, Mahabusarakam W, Tonganunt M, Stafford LJ, Phongdara A, Liu M, et al. (2009) Morelloflavone blocks injury-induced neointimal formation by inhibiting vascular smooth muscle cell migration. Biochim Biophys Acta 1790:31-39.
25. Pyun BJ, Choi S, Lee Y, Kim TW, Min JK, Kim Y, Kim BD, Kim JH, Kim TY, Kim YM, et al. (2008) Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity. Cancer Res 68:227-235.
26. Quesada AR, Muñoz-Chápuli R, and Medina MA (2006) Anti-angiogenic drugs: from bench to clinical trials. Med Res Rev 26:483-530.
27. Roodhart JM, Langenberg MH, Witteveen E, and Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 3:132-143.
28. Simpson-Haidaris PJ, Pollock SJ, Ramon S, Guo N, Woeller CF, Feldon SE, and Phipps RP (2010) Anticancer role of PPARγ agonists in hematological malignancies found in the vasculature, marrow, and eyes. PPAR Res 2010:814609.
29. Stienstra R, Duval C, Müller M, and Kersten S (2007) PPARs, obesity, and inflammation. PPAR Res 2007:95974.
30. Strimpakos AS, Karapanagiotou EM, Saif MW, and Syrigos KN (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35:148-159.
31. Taraboletti G and Giavazzi R (2004) Modelling approaches for angiogenesis. Eur J Cancer 40:881-889.
32. Williams CK, Li JL, Murga M, Harris AL, and Tosato G (2006) Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107:931-939.
33. Yi T, Cho SG, Yi Z, Pang X, Rodriguez M, Wang Y, Sethi G, Aggarwal BB, and Liu M (2008a) Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther 7:1789-1796.
34. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, and Liu M (2008b) Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 68:1843-1850.